China
Three sources explain why a notification by Nanjing’s IP centre in China banning AI use in patent drafting is too broad and could be difficult to enforce
Monday’s coverage includes news of a potentially 'game-changing' trademark development in China and how practitioners are using AI
Heath Hoglund talks about the value proposition of patent pools and why it went ahead with its first-ever series of pool meetings in China
The deal could mean that hundreds of licensees in the pool would have access to a broader range of VVC patents
Sponsored
Sponsored
-
Sponsored by Wanhuida Intellectual PropertyXiaohui Wu of Wanhuida Intellectual Property reports on a ruling by the Supreme People’s Court of China that emphasises that the determination of common knowledge in the assessment of inventiveness should be incontrovertible -
Sponsored by Liu, Shen & AssociatesAn increasing number of foreign companies are conducting research and development in China. Xuelan Yue of Liu Shen & Associates considers the implications and how to incentivise inventors
-
Sponsored by Liu, Shen & AssociatesDanchen Cheng of Liu Shen & Associates discusses the consequences of China’s amended patent law for partial design patent applications
-
Sponsored by Purplevine IPXiaoyan Zhou of Purplevine IP analyses the Fifth Set of Listing Standards for Medical Device Companies on STAR Market of the Shanghai Stock Exchange, which encourages companies to develop core technologies
-
Sponsored by Wanhuida Intellectual PropertyYue Guan of Wanhuida Intellectual Property analyses a decision by the China National Intellectual Property Administration on the validity of a pulmonary hypertension drug and the implications for pharmaceutical patentees
-
Sponsored by Purplevine IPXiaoyan Zhou of Purplevine IP explains how the introduction of administrative measures for registering, and filing records relating to, medical devices in China should affect companies’ IP strategy
